MARKETING GRANTED ORDERS

Philip Morris Products S.A.
Attention: Laura Leigh Oyler, U.S. Agent for PMP S.A., Head of U.S. Regulatory Affairs

FDA Submission Tracking Numbers (STNs): PM0004337.PD1 - PM0004337.PD2

Dear Laura Oyler:

We completed review of your sPMTAs and are issuing marketing granted orders for the tobacco products identified in Appendix A. Our finding that permitting the marketing of the new products is appropriate for the protection of the public health (APPH) does not mean FDA has “approved” the new tobacco products specified in Appendix A; therefore, you may not make any express or implied statement or representation in a label, labeling, or through the media or advertising, that the new tobacco products specified in Appendix A are approved by FDA (see Section 301(tt) of the FD&C Act).

Based on our review of your sPMTAs, we determined that permitting the marketing of the new tobacco products, as described in your applications and specified in Appendix A, is APPH. The issuance of these marketing granted orders confirms that you have met the requirements of section 910(c) of the FD&C Act and authorizes marketing of your new tobacco products. Under the provisions of section 910, you may introduce or deliver for introduction into interstate commerce the tobacco products, in accordance with the marketing order requirements outlined in these orders, including all appendices.

The authority to market the new tobacco products under these orders are also contingent upon the conditions listed in these orders and subject to the requirements in the enclosed appendices.

The requirements in these orders are intended to help ensure that the marketing of your products will continue to be appropriate for the protection of the public health, taking into account, among other factors, initiation among non-users, particularly youth. However, compliance with these requirements alone is not a guarantee that the marketing of the products will remain appropriate for the protection of the public health, particularly if, despite these measures, there is a significant uptake in youth initiation, for example. FDA will continue to monitor the marketing of your products.

Based on our review of your sPMTAs, the marketing restrictions in Appendix D are necessary to our conclusion that permitting the marketing of the new tobacco products is appropriate for the

---

1 Supplemental Premarket Tobacco Product Applications (sPMTAs) submitted under section 910 of the Federal Food, Drug, and Cosmetic Act (FD&C Act). Applicants that have received a marketing granted order for a tobacco product may, as an alternative format of submitting an application that meets the content requirements of 21 CFR 1114.7, submit a supplemental PMTA to seek marketing authorization for modifications to such product, which result in a new tobacco product under section 910(a)(1) of the FD&C Act.
protection of public health. Absent these restrictions, a marketing granted order for these applications could not issue consistent with the requirements of section 910(c) of the FD&C Act. We also recommend that you take additional steps to limit youth exposure to your print and point-of-sale advertising, including, for example, limiting advertising to print publications where 85% or more of the readership is 21 years of age or older and/or selecting publications that do not over-index for youth, requiring advertising to be placed inside the store, and placing product displays near other age-restricted products and away from toys and candy.

FDA is requiring that the products subject to this order adhere to the same marketing requirements that FDA found necessary for the products subject to marketing authorization on April 30, 2019; however, based on current experience we have updated the timelines for reporting.

**Additionally, these orders are conditioned upon the products conforming with any applicable current or future tobacco product standards, unless specifically exempted under these orders or the product standard(s).**

The products subject to these marketing granted orders are subject to withdrawal or temporary suspension as described in section 910(d) of the FD&C Act.

You may be eligible to submit an sPMTA, in accordance with 21 CFR 1114.15, for modification(s) made to tobacco products that received marketing granted orders, by cross-referencing content in the PMTA and postmarket reports for the original tobacco products subject to this letter. Applicants that have questions about whether it would be appropriate to submit an sPMTA for modification(s) they are seeking to implement should contact their Regulatory Health Project Manager (RHPM) within the Office of Science for more information.

We remind you that all regulated tobacco products, including the tobacco products specified in Appendix A, are subject to the requirements of the FD&C Act and its implementing regulations. These requirements include, but are not limited to, annual registration, listing of products, listing of ingredients, reporting of harmful and potentially harmful constituents, packaging, labeling, and advertising requirements, and payment of user fees. It is your responsibility to ensure the tobacco products specified in Appendix A comply with all applicable statutory and regulatory requirements. FDA will monitor your compliance with all applicable statutes and regulations.

In accordance with 40 CFR 1506.6, we will make your Environmental Assessment (EA) publicly available.

If you discontinue the manufacture, preparation, compounding or processing for commercial distribution of these tobacco products and later decide to reintroduce the products into the market, please contact the Office of Science prior to reintroduction.

---

2 We note that any modifications made to a tobacco product would render it a new tobacco product that would be subject to the premarket review requirements under section 910 of the FD&C Act.
We encourage you to submit all regulatory correspondence electronically via the CTP Portal\textsuperscript{3,4} using eSubmitter.\textsuperscript{5} Alternatively, submissions may be mailed to:

Food and Drug Administration  
Center for Tobacco Products  
Document Control Center (DCC)  
Building 71, Room G335  
10903 New Hampshire Avenue  
Silver Spring, MD 20993-0002

The CTP Portal and FDA’s Electronic Submission Gateway (ESG) are generally available 24 hours a day, seven days a week; if the upload is successful, submissions are considered received by DCC on the day of upload. Submissions delivered to DCC by courier or physical mail will be considered timely if received during delivery hours on or before the due date\textsuperscript{6}; if the due date falls on a weekend or holiday, the delivery must be received on or before the preceding business day. We are unable to accept regulatory submissions by e-mail.

If you have any questions, please contact Elizabeth Do, Regulatory Health Project Manager, at (301) 796 - 5205 or Elizabeth.Do@fda.hhs.gov.

If you have any questions regarding postmarket activities for the tobacco products subject of these orders, please contact Chad Burger, Director, Division of Product Compliance, at CTP-OCE-Postmarket@fda.hhs.gov.

Sincerely,

/S/

Benjamin Apelberg, Ph.D.  
Director (Acting)  
Office of Science  
Center for Tobacco Products

Enclosures:  
   Appendix A – New Tobacco Products Subject of This Letter  
   Appendix B – Postmarket Recordkeeping and Retention  
   Appendix C – Postmarket Reporting  
   Appendix D – Marketing Restrictions

\textsuperscript{3} https://www.fda.gov/tobacco-products/manufacturing/submit-documents-ctp-portal  
\textsuperscript{4} FDA’s Electronic Submission Gateway (ESG) is still available as an alternative to the CTP Portal.  
\textsuperscript{5} https://www.fda.gov/industry/fda-esubmitter  
\textsuperscript{6} https://www.fda.gov/tobacco-products/about-center-tobacco-products-ctp/contact-ctp
Appendix A

New Tobacco Products Subject of This Letter

<table>
<thead>
<tr>
<th>Common Attributes of PMTAs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Submission date</td>
</tr>
<tr>
<td>Receipt date</td>
</tr>
<tr>
<td>Applicant</td>
</tr>
<tr>
<td>Product manufacturer</td>
</tr>
<tr>
<td>Product category</td>
</tr>
<tr>
<td>Product subcategory</td>
</tr>
<tr>
<td>Attributes</td>
</tr>
<tr>
<td>STN</td>
</tr>
<tr>
<td>Static Product ID</td>
</tr>
<tr>
<td>Product Name</td>
</tr>
<tr>
<td>Package Type</td>
</tr>
<tr>
<td>Package Quantity</td>
</tr>
<tr>
<td>Characterizing Flavor</td>
</tr>
<tr>
<td>Nicotine Source</td>
</tr>
<tr>
<td>Diameter</td>
</tr>
<tr>
<td>Product Length</td>
</tr>
<tr>
<td>Ventilation</td>
</tr>
<tr>
<td>Additional Property</td>
</tr>
</tbody>
</table>

| STN                                        | PM0004337                 |
| Static Product ID                          | PD2                       |
| Product Name                               | Marlboro Bronze HeatSticks |
| Package Type                               | Box                       |
| Package Quantity                           | 20 HeatSticks             |
| Characterizing Flavor                      | Tobacco                   |
| Nicotine Source                            | Tobacco                   |
| Diameter                                   | 7.42 mm                   |
| Product Length                             | 45 mm                     |
| Ventilation                                | Not Applicable            |
| Additional Property                        | Source of energy: Electric (rechargeable battery) |

---

7 Brand/sub-brand or other commercial name used in commercial distribution.
8 Effective April 14, 2022, FDA’s authority to regulate tobacco products was extended to include tobacco products containing nicotine from any source. As such, nicotine source is considered a required property for unique identification. https://www.congress.gov/bill/117th-congress/house-bill/2471
9 The IQOS products meet the definitions of cigarette in section 900(3) of the FD&C Act and components and parts in 21 CFR 1100.3 and 1141.3. Cigarettes and their components and parts must comply with the applicable provisions of the FD&C Act and regulations. For purposes of scientific review, the product category and subcategory have been revised.
10 The characterizing flavor previously identified as “None” has been updated in FDA records to “Tobacco” to accurately reflect that the product provides a tobacco characterizing flavor from the filler. As such, this product does not have any change in characterizing flavor.
11 For this product, neither filter efficiency nor ventilation are used to control aerosol deliveries.
12 The components and assemblies control the delivery of energy. The critical items include the Heater Printed Circuit Board Assembly (PCBA) comprising the heating blade and the battery.
Appendix B

Postmarket Recordkeeping and Retention

Under section 910(f) of the FD&C Act, this order requires that you establish and maintain the records listed below. At any time during the retention period described in this order, FDA may request that you provide any of the documents described below. In addition, under section 704 of the FD&C Act, FDA may inspect your establishment(s) and request to inspect any record(s) described below.

The following records must be retained according to the retention periods described below. These records must be legible, in English, and available for inspection and copying by officers or employees duly designated by the Secretary, upon request.

<table>
<thead>
<tr>
<th>Record</th>
<th>Description</th>
<th>Retention Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior PMTAs</td>
<td>Each PMTA submitted prior to marketing orders</td>
<td>4 years from the date that FDA issues the marketing order</td>
</tr>
<tr>
<td>Postmarket reports</td>
<td>Postmarket reports, including periodic and adverse experience reports as described in this order</td>
<td>4 years from the date the report was submitted to FDA or until FDA inspects the records, whichever occurs sooner</td>
</tr>
<tr>
<td>Correspondence with FDA</td>
<td>Correspondence with FDA pertaining to each authorized product</td>
<td>4 years from the date of distribution of the last batch of each product subject to this order</td>
</tr>
<tr>
<td>Study data</td>
<td>Nonclinical or clinical study documentation including:</td>
<td>4 years from the date of the order or 4 years from the conclusion of the study, whichever occurs later</td>
</tr>
<tr>
<td></td>
<td>- Source data;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Study protocols (including statistical analysis plan) and amendments showing the dates and reasons for each protocol revision;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Institutional Review Board (IRB) or Independent Ethics Committee (IEC) approvals;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Informed consent forms;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Correspondence with study monitors/investigators/contract research organizations/sponsors/IRB/IEC;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Investigator financial disclosure statements;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Progress reports;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Monitoring reports;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Adverse experience reports;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Case report forms/subject diaries/medical records/laboratory reports;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Subject data line listings/observations records;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Test article accountability records;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Study results/protocol summaries/study reports;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Certifications and amendments to certifications</td>
<td></td>
</tr>
<tr>
<td>Record</td>
<td>Description</td>
<td>Retention Period</td>
</tr>
<tr>
<td>--------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Manufacturing records</td>
<td>Records pertaining to the manufacture, in process and release testing, production process (including any changes to the process, facility, or controls), packaging, storage, and stability monitoring and testing (including protocol and results)  \   \   Records and reports of all manufacturing deviations, investigations, and corrective and preventive actions including, but not limited to, those deviations associated with processing, testing, packing, labeling, storage, holding and distribution; and any deviation that may affect the characteristics of each final product</td>
<td>4 years from the date of distribution of each batch of each product subject to this order</td>
</tr>
<tr>
<td>Sales and/or distribution records</td>
<td>A list of distributors and retailers of the products, including brick-and-mortar and digital¹³ (including internet/online and mobile)</td>
<td>4 years from the date of distribution of each batch of each product subject to this order</td>
</tr>
<tr>
<td></td>
<td>Any available information (not to include personally identifiable information) about product purchasers, such as purchasers’ demographics (e.g., age, gender, race/ethnicity, geographic region) and previous or current use of other tobacco products (i.e., dual use)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>With respect to individuals under the federal minimum age of sale of tobacco products, policies and procedures regarding restrictions on access to the products, including purchaser age and identity verification processes</td>
<td></td>
</tr>
<tr>
<td>Complaints</td>
<td>Records pertaining to any and all complaints associated with the tobacco product that is the subject of this order; such records may also include your analysis of those complaints</td>
<td>4 years from the date of distribution of each batch of each product subject to this order</td>
</tr>
<tr>
<td>Health hazard analysis</td>
<td>Health hazard analyses, if performed voluntarily or directed by FDA</td>
<td>4 years from the date of distribution of each batch of each product subject to this order</td>
</tr>
<tr>
<td>Labeling</td>
<td>Specimens of all labeling (including all labeling variations, such as those reflecting different required warnings), labels, inserts/onserts, instructions, and other accompanying information</td>
<td>4 years from the date of initial dissemination to the public</td>
</tr>
<tr>
<td>Advertising, marketing and promotional materials and plans</td>
<td>Copies of all advertising, marketing, and/or promotional materials published, disseminated to consumers, or for use in engaging or communicating with consumers</td>
<td>4 years from the date of initial dissemination to the public or implementation</td>
</tr>
</tbody>
</table>

¹³ For the purposes of this order, here and throughout the document, “digital” includes internet/online and mobile.
<table>
<thead>
<tr>
<th>Record</th>
<th>Description</th>
<th>Retention Period</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Copies of all advertising and marketing plans including strategic creative briefs and paid media plans, by channel and by product, and the details, dollar amount(s) and flighting of such plans, by channel and by product, including any:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Use of competent and reliable data sources, methodologies, and technologies to establish, maintain, and monitor highly targeted advertising and marketing plans and media buys, including a list of all data sources used to target advertising and marketing plans and media buys;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Targeting of specific group(s) by age-range(s), including young adults, ages 21-24, and other demographic or psychographic characteristics that reflect your intended audience(s), including the source(s) of such data;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- With respect to individuals under the federal minimum age of sale of tobacco products, actions taken to restrict access to the products and limit exposure to the products’ labeling, advertising, marketing, and/or promotion;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Use of owned, earned, shared, or paid media to create labeling for, advertise, market, and/or promote the products;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Use of partners, influencers, bloggers, or brand ambassadors to create labeling for, advertise, market, and/or promote the products;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Consumer engagements – whether conducted by you, on your behalf, or at your direction - including events at which the products will be demonstrated and how access will be restricted to individuals at or above the federal minimum age of sale of tobacco products; or</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Use of public relations or other communications outreach to create labeling for, advertise, market, and/or promote the products;</td>
<td></td>
</tr>
<tr>
<td>Record</td>
<td>Description</td>
<td>Retention Period</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------------------------------</td>
</tr>
<tr>
<td>Formative consumer research</td>
<td>Copies of any formative research studies conducted among any audiences, in the formation of the labeling, advertising, marketing, and/or promotional materials, including qualitative and quantitative research studies used to determine message effectiveness, consumer knowledge, attitudes, beliefs, intentions, and behaviors toward using the products, and including copies of the stimuli used in testing</td>
<td>4 years after the studies are completed</td>
</tr>
<tr>
<td>Consumer evaluation research</td>
<td>Copies of any consumer evaluation research studies conducted among any audiences to determine the effectiveness of the labeling, advertising, marketing, and/or promotional materials and any shifts in consumer knowledge, attitudes, beliefs, intentions, and behaviors toward using the products, and including copies of the stimuli used in testing</td>
<td>4 years after the studies are completed</td>
</tr>
<tr>
<td>Contractual agreements</td>
<td>Copies of any contractual agreements regarding the creation or dissemination of the products’ labeling, advertising, marketing, and/or promotional materials, including, for example, in print media, online or through digital platforms (e.g., social media and mobile applications), such as influencers, bloggers, and ambassadors, on your behalf, or at your direction</td>
<td>4 years from the date of the contract or until the contract expires, whichever is later</td>
</tr>
</tbody>
</table>
Appendix C
Postmarket Reporting

I. Annual Reporting

Under section 910(f) of the FD&C Act, these orders require that you submit the following postmarket reports to FDA on an annual basis, beginning twelve months from the date of the order to help FDA determine whether continued marketing of each new tobacco products are appropriate for the protection of public health or whether there is or may be other grounds for withdrawing or temporarily suspending such order. For each 12-month reporting period, the report must include:

1. A single submission with a cover letter that includes the following subject line: **ANNUAL REPORT for PM0004337.PD1 - PM0004337.PD2.** The cover letter should include the STN(s) and corresponding tobacco product name(s), applicant name, date of report, reporting period, and marketing status outside the United States;

2. All final printed labeling (including all variations, such as those reflecting different required warnings) not previously submitted (e.g., if previously submitted under section 905(i) or previously submitted at the last reporting period and no changes were made, please list the date and manner of submission), including the date the labeling was first disseminated and the date when the labeling was discontinued, and a description of all changes to the labeling. The labeling must include all the panels and be presented in the actual size and color with legible text. The labeling must include labels, inserts/onserts, instructions, and any other accompanying information or materials for the products;

3. All final full-color advertising, marketing, and/or promotional materials, published, disseminated to consumers, or for use in engaging or communicating with consumers not previously submitted (e.g., if previously submitted under 905(i) or previously submitted at the last reporting period and no changes were made, please list the date and manner of submission), along with the original date such materials were first disseminated and the date they were discontinued, and a description of all changes to the materials. The materials must be legible, include all panels where applicable (e.g., print ads, point of sale signs) and reflect the actual size and colors used. For any materials that would not fit on an 8.5” x 11” piece of paper, you may resize and submit electronic versions of such materials in a format that FDA can review and with sufficient resolution to allow FDA to read lettering clearly. If resizing the advertisement does not allow for text to be read easily, the complete text must be provided separately and clearly referenced. Digital media, such as videos and animations must be submitted in a format that FDA is able to open and review;

4. A description of each change made to the manufacturing, facilities, or controls during the reporting period, including:
   a. A comparison of each change to what was described in the PMTAs;
   b. The rationale for making each change and, if any, a listing of any associated changes; and
   c. The basis for concluding that each change does not result in a new tobacco product that is outside the scope of the marketing granted order.
5. A summary of any stability monitoring, and testing of the products, including the monitoring and testing protocol(s) (including batch/lot sampling) and results;

6. A complete list of ongoing and completed studies about the tobacco products conducted by, or on your behalf, that have not been previously reported;

7. Full reports of information published or known to you, or which should be reasonably known to you, concerning scientific investigations and literature about the tobacco products that have not been previously reported, as well as significant findings from publications not previously reported;

8. A summary and analysis of all serious and unexpected adverse experiences associated with the tobacco products that have been reported to you or that you are aware of, accompanied by a statement of any changes to the overall risk associated with the tobacco products, and a summary of any changes in the health risks, including the nature and frequency of the adverse experience, and potential risk factors;

9. A summary of sales and distribution of the tobacco products for the reporting period, to the extent that you collect or receive such data, including:
   a. Total U.S. sales reported in dollars, units, and volume with breakdowns by U.S. census region, major retail markets, and channels in which the products are sold;
   b. The Universal Product Code that corresponds to the products identified in the PMTA; and
   c. Demographic characteristics of products purchasers, such as age, gender, race/ethnicity, geographic region, and tobacco use status;

10. A summary of the implementation and effectiveness of your policies and procedures regarding verification of the age and identity of purchasers of the products;

11. A summary of the implementation and effectiveness of your policies and procedures regarding restrictions on access to the products for individuals under the federal minimum age of sale of tobacco products;

12. A summary of all formative consumer research studies conducted—whether by you, on your behalf, or at your direction—among any audiences, in the formation of new labeling, advertising, marketing, and/or promotional materials, not previously submitted, including qualitative and quantitative research studies used to determine message effectiveness, consumer knowledge, attitudes, beliefs, intentions and behaviors toward using the products, and including the findings or these studies and copies of the stimuli used in testing;

13. A summary of all consumer evaluation research studies conducted—whether by you, on your behalf, or at your direction—among any audiences, not previously submitted, to determine the effectiveness of labeling, advertising, marketing, and/or promotional materials and shifts in consumer knowledge, attitudes, beliefs, intentions, and behaviors toward using the products, and including the findings of these studies and copies of the stimuli used in testing;

14. A summary of the creation and dissemination of the products’ labeling, advertising, marketing, and/or promotional materials—whether conducted by you, on your behalf, or at your direction
– including a list of all entities involved and a description of their involvement, including a description of contractual agreements with such entities;

15. A description of the implementation of all advertising and marketing plans – whether conducted by you, on your behalf, or at your direction - not previously submitted, including strategic creative briefs and paid media plans by channel and by product, and the details, dollar amount(s) and flighting of such plans, by channel and by product, including a description of any:
   a. Use of competent and reliable data sources, methodologies, and technologies to establish, maintain, and monitor highly targeted advertising and marketing plans and media buys, including a list of all data sources used to target advertising and marketing plans and media buys;
   b. Targeting of specific group(s) by age-range(s), including young adults, ages 21-24, and other demographic or psychographic characteristics that reflect the intended audience(s), including the source(s) of such data;
   c. With respect to individuals under the federal minimum age of sale of tobacco products, actions taken to restrict access to the products and limit exposure to the products’ labeling, advertising, marketing, and/or promotion;
   d. Use of owned, earned, shared, or paid media to create labeling for, advertise, market, and/or promote the products;
   e. Use of partners, influencers, bloggers, and/or brand ambassadors to create labeling for, advertise, market, and/or promote the products;
   f. Consumer engagements – whether conducted by you, on your behalf, or at your direction – including events at which the products were demonstrated and how access was restricted to individuals at or above the federal minimum age of sale of tobacco products; or
   g. Use of public-relations or other communications outreach to create labeling for, advertise, market, and/or promote the products; including the original date such plans were first used and the date they were discontinued, and a description of all changes to such plans since the last periodic report, by channel and by product;

16. A summary of media tracking and optimization, by channel, by product, and by audience demographics (e.g., age, gender, race/ethnicity, geographic region), including a summary of real-time digital media monitoring to identify, correct, and prevent delivery of advertising impressions to individuals under the federal minimum age of sale of tobacco products, and including a summary of implementation of any corrective and preventive measures, not previously submitted;

17. An analysis of the actual delivery of advertising impressions, by channel, by product, and by audience demographics (e.g., age, gender, race/ethnicity, geographic location), including a breakout by age-group (i.e., adults, ages 25+; young adults, ages 18-24; and youth, ages 12-17 and ages 11 and under), not previously submitted. This analysis must be verified against post-launch delivery-verification reports submitted to you from an accredited source; and

18. An overall assessment of how the marketing of the tobacco products continues to be appropriate for the protection of public health.

The products subject to these marketing granted orders are subject to withdrawal or temporary suspension as described in section 910(d) of the FD&C Act. Grounds that FDA will consider for
withdrawal under section 910(d) of the FD&C Act include scenarios in which FDA finds that the 
continued marketing of the product is no longer APPH. These scenarios may include, but are not limited 
to, certain changes in product use behaviors that were not expected in FDA’s assessment of the PMTA 
(e.g., increases in the percentage or number of youth and young adults who report use of your products, 
fewer users of potentially more harmful products switching to your products than anticipated), changes 
in FDA’s understanding of the net effects of your products on the population as a whole, or new 
scientific evidence that demonstrates that the products present a greater risk to health than FDA 
understood during the review process.

II. Serious and Unexpected Adverse Experiences Reporting and Reporting of Certain Manufacturing 
Deviations

Under section 910(f) of the FD&C Act, these orders require that you report to the FDA all adverse 
experiences that are both serious and unexpected and your analysis of the association between the 
adverse experience and each new tobacco product **within 15 calendar days** after the report is received 
by you. These experiences may become known to you through any source including a customer 
complaint, request, or suggestion made as a result of an adverse experience, a manufacturing deviation 
analysis, tobacco product defect, or failure reported to you; or identified in the literature or media. 
Your information should be submitted with a cover letter that includes the following subject line: 
**SERIOUS UNEXPECTED ADVERSE EXPERIENCE REPORT for PM0004337.P1 – PM0004337.PD2.**

For purposes of reporting under these orders, **serious adverse experience** means an adverse experience 
that results in any of the following outcomes:

- Death;
- A life-threatening condition or illness;
- Inpatient hospitalization or prolongation of existing hospitalization;
- A persistent or significant incapacity or substantial disruption in the ability to conduct normal 
  life functions;
- A congenital anomaly/birth defect; or
- Any other adverse experience that, based upon appropriate medical judgment, may jeopardize 
  the health of a person and may require medical or surgical intervention to prevent one of the 
  other outcomes listed in this definition.

For purposes of reporting under these orders, **unexpected adverse experience** means an adverse 
experience occurring in one or more persons in which the nature, severity, or frequency of the 
experience is not consistent with:

- The known or foreseeable risks of adverse experiences associated with the use or exposure to 
  each tobacco product as described in the PMTA and other relevant sources of information, such 
  as postmarket reports and studies;
- The expected natural progression of any underlying disease, disorder, or condition of the 
  persons(s) experiencing the adverse experience and the person’s predisposing risk factor profile 
  for the adverse experience; or
- The results of nonclinical laboratory studies.
For products that have been distributed, if a manufacturing deviation occurs that you determine presents a reasonable probability that the tobacco product contains a manufacturing or other defect not ordinarily contained in tobacco products on the market that would cause serious, adverse health consequences or death you are required to report the deviation to FDA within 15 calendar days of identification.

III. Notifications

Under sections 910(c)(1)(B) and 910(f) of the FD&C Act, these orders also require that, as of the authorization date of your marketing granted orders, you submit the following notifications of your marketing plans and materials to FDA. This requirement to submit the product’s labeling, advertising, marketing, and promotional materials and plans in advance of their use is not for pre-approval – that is, FDA is not requiring that it review and approve such materials or plans before they may be used. Rather, such advance notification will provide FDA timely access to such materials and plans and, if needed, allow FDA to provide advisory comments, including any concerns about their possible impact on youth appeal and tobacco use initiation. You may begin disseminating the materials 30 days after providing notification to FDA.

This notification must be received by FDA at least 30 days prior to dissemination, which includes but is not limited to the publication, dissemination to consumers, or use in engaging or communicating with consumers of such materials. The duration of these notification requirements is as follows:

- For a period of six months starting with the initial dissemination of the materials, provide notification of all labeling, advertising, marketing, and promotion.

Each 30-day notification must include:

1. A single submission with a cover letter that includes the following subject line: **30-DAY NOTIFICATION for PM0004337.PD1 – PM0004337.PD2**. The cover letter should include the STN(s) and corresponding tobacco product name(s), applicant name, date of notification, and planned dissemination date;

2. Full-color copies of all such labeling, advertising, marketing, and promotional materials for the products. The materials must be legible, include all panels where applicable (e.g., print ads, point of sale signs) and reflect the actual size and colors used. For any materials that would not fit on an 8.5” x 11” piece of paper, you may resize and submit electronic versions of such materials in a format that FDA can review and with sufficient resolution to allow FDA to read all lettering clearly. If resizing the advertisement does not allow for text to be read easily, the complete text must be provided separately and clearly referenced; and

3. All advertising and marketing plans, including strategic creative briefs and paid media plans, by channel and by product, and the details, dollar amount(s) and flighting of such plans, by channel and by product, including any plans to:
   a. Use competent and reliable data sources, methodologies, and technologies to establish, maintain, and monitor highly targeted advertising and marketing plans and media buys, including a list of all data sources used to target advertising and marketing plans and media buys;
b. Targeting specific group(s) by age-range(s), including young adults, ages 21-24, and other demographic or psychographic characteristics that reflect your intended audience, including the source(s) of such data;

c. With respect to individuals below the federal minimum age of sale of tobacco products, actions taken to restrict access and exposure to the products’ labeling, advertising, marketing, and/or promotion;

d. Use owned, earned, shared, or paid media to create labeling for, advertise, market, and/or promote the products;

e. Use partners, influencers, bloggers, or brand ambassadors to create labeling for, advertise, market, and/or promote the products;

f. Conduct consumer engagements – whether by you, on your behalf, or at your direction – including events at which the products will be demonstrated and how access will be restricted to individuals at or above the federal minimum age of sale of tobacco products; or

g. Use public-relations or other communications outreach to create labeling for, advertise, market, and/or promote the products.
Appendix D
Marketing Restrictions

Under section 910(c)(1)(B) of the FD&C Act, and in accordance with section 202(a) of the Family Smoking Prevention and Tobacco Control Act, these orders require you to:

- Include the warning statement: “WARNING: This product contains nicotine. Nicotine is an addictive chemical.” on the package labels of all HeatSticks packs and of all kits containing HeatSticks packs as well as in all advertisements for such products and kits. Specifically, the warning statement must appear directly on the package and must be clearly visible underneath any cellophane or other clear wrapping as follows:
  - Be located in a conspicuous and prominent place on the two principal display panels of the package and the warning area must comprise at least 30 percent of each of the principal display panels;
  - Be printed in at least 12-point font size and the warning statement must occupy the greatest possible proportion of the warning area set aside for the required text;
  - Be printed in conspicuous and legible Helvetica bold or Arial bold type (or other sans serif fonts) and in black text on a white background or white text on a black background in a manner that contrasts by typography, layout, or color, with all other printed material on the package;
  - Be capitalized and punctuated as indicated in this order; and
  - Be centered in the warning area in which the text is required to be printed and positioned such that the text of the warning statement and the other information on the principal display panel have the same orientation.

- For print advertisements and other advertisements with a visual component (including, for example, advertisements on signs, shelf-talkers, websites, mobile applications, and e-mail), the warning statement must appear in the upper portion of the area of the advertisement within the trim area as follows:
  - Occupy at least 20 percent of the area of the advertisement;
  - Appear in at least 12-point font size and the warning statement must occupy the greatest possible proportion of the warning area set aside for the required text;
  - Appear in conspicuous and legible Helvetica bold or Arial bold type (or other similar sans serif fonts) and in black text on a white background or white text on a black background in a manner that contrasts by typography, layout, or color, with all other material on the advertisement;

---

14 When the final rule for cigarette health warnings goes into effect, FDA will reevaluate the conditions of marketing with respect to warnings for the products subject to this order.

15 This warning must appear on each package and each advertisement, in addition to the rotating Surgeon General warnings required under FCLAA (except the carbon monoxide warning, which is to be removed from the rotation of the Surgeon General warnings as described in this order).
Be capitalized and punctuated as indicated in this order;

Be centered in the warning area in which the text is required to appear and positioned such that the text of the warning statement and the other textual information in the advertisement have the same orientation; and

Be surrounded by a rectangular border that is the same color as the text of the warning statement and that is not less than 3 millimeters (mm) or more than 4 mm.

- Removal of the warning: “SURGEON GENERAL’S WARNING: Cigarette Smoke Contains Carbon Monoxide.” from the required warnings to be displayed on the product package labels and advertisements under the Federal Cigarette, Labeling and Advertising Act (FCLAA).


Under section 910(c)(1)(B) of the FD&C Act, this order also requires you to:

- For any digital sales – whether conducted by you, on your behalf, or at your direction – establish, maintain, and monitor use of independent age- and identity-verification service(s) that compare customer information against independent, competent, and reliable data sources, such as public records, to prevent the sale of the products to individuals who are under the federal minimum age of sale of tobacco products.

- For any of the products’ labeling, advertising, marketing, and/or promotion appearing in your owned digital properties (e.g., your company-owned, consumer-directed, product-branded website(s) and/or mobile applications) – whether conducted by you, on your behalf, or at your direction – establish, maintain, and monitor use of independent age- and identity-verification service(s) that compare customer information against independent, competent, and reliable data sources, such as public records, at the first point of access to such properties, to restrict access to such labeling, advertising, marketing, and/or promotion to only individuals who are at or above the federal minimum age of sale of tobacco products.

- For any of the products’ labeling, advertising, marketing, and/or promotion appearing in any shared digital properties (e.g., your product-branded social media accounts, pages and associated content; content promoting your products on your behalf disseminated through another entity’s social media accounts) – whether conducted by you, on your behalf, or at your direction – establish, maintain, and monitor use of the available site-, platform- and content- (e.g., post, video) specific age-restriction controls (e.g., age-restrict an entire product-branded account and all associated content disseminated through such account; ensure age-restriction of a specific video disseminated by an influencer promoting the products on your behalf through the influencer’s account), at the first point of access to such properties, to restrict access to such labeling, advertising, marketing, and/or such promotion to only individuals who are at or above the federal minimum age of sale of tobacco products.

- For any of the products’ labeling, advertising, marketing, and/or promotion appearing in paid digital media (e.g., paid digital banner advertisements for the products running on another
company’s website; paid advertising for the products running in social media; paid distribution of influencer content; paid advertising in streaming/Over-The-Top video programming; paid advertising in streaming/internet radio content) – whether conducted by you, on your behalf, or at your direction:

- Establish, maintain, and monitor use of competent and reliable data sources, methodologies, and technologies to precisely target delivery of such labeling, advertising, marketing, and/or promotion to only individuals who are or above the federal minimum age of sale of tobacco products. Such targeting must use only first- and/or second-party age-verified data, where:
  - “First-party” age-verified data is data owned by you (e.g., your customer registration data collected via site traffic to your company-owned website; data you use in direct marketing to your adult smoking customers) that you have age-verified through independent, competent, and reliable data sources; and
  - “Second-party” age-verified data is first-party data owned and age-verified by another competent and reliable entity (e.g., another company’s first-party user registration data) to which you have access. Such data must be age-verified by the second party.
  - “First-party” and “second-party” data does not include data obtained from data aggregators who categorize consumers based on trackable activities and inferred interests (e.g., internet search terms, video interactions, browsing history, purchasing behaviors) to create demographic and psychographic profiles marketers may use to enhance audience targeting. Such data is not considered age-verified and can only be used in combination with first- and/or second-party age-verified data.

- Establish, maintain, and monitor use of competent and reliable data sources, methodologies, and technologies (e.g., using an embedded tracking pixel in all digital advertising) – whether conducted by you, on your behalf, or at your direction – to track and measure actual delivery of all advertising impressions, by channel, by product, and by audience demographics (e.g., age, gender, race/ethnicity, geographic region). Such monitoring requires real-time digital media tracking, and identifying, correcting, and preventing delivery of advertising impressions to individuals under the federal minimum age of sale of tobacco products. Such monitoring also requires post-launch delivery verification reports for other paid media be submitted to you or entities working on your behalf or at your direction from an accredited source.

- For any use of partners, influencers, bloggers, and/or brand ambassadors to create labeling for, advertise, market, and/or promote the products – whether conducted by you, on your behalf, or at your direction – disclose to consumers or viewers, via the use of statements such as “sponsored by [firm name]” in such labeling, advertising, marketing, and/or promotional materials, any relationships between you and entities that create labeling for, advertise, market, and/or promote the products, on your behalf, or at your direction.